ALDX | Ticker Profile - Titan Protect

ALDX

Aldeyra Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$1.63

Data: 2026-05-13

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$101M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-7.88

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-51.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.60

+366% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

https://www.aldeyra.com

Country: United States Employees: 7 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

15.4% PASS

Debt must be below 33% of total assets

Cash Ratio

64.3% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.471

Positive but modest risk-adjusted returns

Kelly Fraction

0.0264

Modest edge detected — smaller position warranted

Calmar Ratio

-0.385

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-31.7%

Historical annualised return based on price data

Max Drawdown

-82.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.15

Moves slightly more than the broader market

52W High

$6.18

74% below the year high

52W Low

$1.07

52% above the year low

Avg Volume

3,084,495

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

12.6%

Elevated short interest — bears are positioned against this

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.45

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.37

Conservative use of debt — low financial risk

Current Ratio

2.72

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.67

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-19,602,224

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-27,369,780

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$13.00

Target Median

$7.60

Target Low

$2.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-03-19	DOUGLAS RICHARD H	Director	70,000	$128,100
2026-03-18	ALFIERI MICHAEL L	Chief Financial Officer	5,000	$7,100
2025-08-13	ALFIERI MICHAEL L	Chief Financial Officer	2,500	$13,250
2025-08-11	MACHATHA STEPHEN	Officer	22,073	$113,713
2025-04-03	PERCEPTIVE ADVISORS L L C	Beneficial Owner of more than 10% of a Class of Security	3,400,000	$4,828,000
2024-08-12	MACHATHA STEPHEN	Officer	16,041	$75,975
2024-08-12	GREENBERG BRUCE	Chief Financial Officer	10,834	$51,313

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go